ARTL Artelo Biosciences, Inc.
$5.43▼ -3.55%
Healthcare
Other
After hours
$5.31▼ -2.21%
Sep 11, 7:36 PM ET
Volume 38.0K
Avg Volume (10D) 121.1K
Key Metrics & Fundamentals
Market Cap
$2.97M
P/E Ratio
–
Div Yield
–%
52W Range
4.68 - 179.19
% vs 50 MA
-28.20%
% vs 200 MA
-81.20%
RSI-14
31.9
MACD Histogram
+0.0500
Beta (1Y vs SPY)
-1.52
Free Cash Flow
-$5.03M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.46M
COGS
–
Operating Exp
$2.51M
Operating Income
-$2.51M
EBIT
-$2.51M
Pretax Income
-$2.43M
Net Income
-$2.43M
EPS (Diluted)
-0.89
Price & Volume History
Loading chart…
Recent News
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 8, 2026 1:00 PM
Artelo Biosciences Announces Reverse Stock Split
GlobeNewswire · Aug 27, 2026 12:00 PM
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
GlobeNewswire · Aug 20, 2026 12:52 PM
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
GlobeNewswire · Aug 17, 2026 12:52 PM
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
GlobeNewswire · Aug 13, 2026 12:00 PM
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
GlobeNewswire · Jul 22, 2026 12:39 PM
Artelo Biosciences Says New Data Shows ART26.12 Reduces Osteoarthritis Pain
MT Newswires · Jul 16, 2026 1:38 PM
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
GlobeNewswire · Jul 16, 2026 12:48 PM
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
GlobeNewswire · Jul 14, 2026 12:47 PM
Artelo Says ART27.13 Decreases Neuropathic Pain-linked Behaviors in Animals Treated With Paclitaxel
MT Newswires · Jul 13, 2026 1:31 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ARTL's money flow as a full page
Social Sentiment
Avg +0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.